Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose
Phase 3
Completed
NCT03999996
| Condition | Dengue Fever |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Takeda |
|---|
| Status | Completed |
|---|
| Enrollment | 365 participants |
|---|
| Interventions | Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) |
|---|
| Start date | Nov 12, 2019 |
|---|
| Completion date | May 25, 2024 |
|---|
| Results posted | Jun 12, 2025 |
|---|
Summary
The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-304 (NCT03423173) (United States \[US\]) and to describe the impact of a tetravalent dengue vaccine (TDV) booster dose vs placebo on antibody response for each of the 4 dengue serotypes at 1 month and 6 months post administration of the TDV booster or placebo.
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])
Month 0 (Day 1) · titer
| Prior to Booster: DEN-304 | 76.8 titer |
|---|
| Prior to Booster: DEN-315 | 88.6 titer |
|---|
| Prior to Booster: DEN-304 | 539.6 titer |
|---|
| Prior to Booster: DEN-315 | 425.6 titer |
|---|
| Prior to Booster: DEN-304 | 33.7 titer |
|---|
| Prior to Booster: DEN-315 | 29.5 titer |
|---|
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 2 (Month 12)
Month 12 · titer
| Prior to Booster: DEN-304 | 58.4 titer |
|---|
| Prior to Booster: DEN-315 | 96.4 titer |
|---|
| Prior to Booster: DEN-304 | 427.3 titer |
|---|
| Prior to Booster: DEN-315 | 276.1 titer |
|---|
| Prior to Booster: DEN-304 | 32.8 titer |
|---|
| Prior to Booster: DEN-315 | 25.3 titer |
|---|
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 3 (Month 15) (DEN-304)
Month 15 (DEN-304) · titer
| Prior to Booster: DEN-304 | 121.7 titer |
|---|
| Prior to Booster: DEN-304 | 560.2 titer |
|---|
| Prior to Booster: DEN-304 | 40.3 titer |
|---|
| Prior to Booster: DEN-304 | 37.6 titer |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.